Greg Macpherson, BPharm CEO/President MITOCHONDRIA AND MITOQ – A RESEARCH UPDATE
Company History Discovered at Otago University, Launch of Launch of MitoQ Supplement Dunedin, Clinical trial Clinical trial New Zealand for PD for Hep C Skincare range Mitochondria and MitoQ – A Research Update
Company History Mitochondria and MitoQ – A Research Update
Company History Mitochondria and MitoQ – A Research Update
Company History We now have well over.. 200,000 100+ patient months countries experience SA GRAS 12 SKUs and growing Mitochondria and MitoQ – A Research Update
Company Mission Our mission is to raise awareness of mitochondria and the link between optimal mitochondria function health and longevity Mitochondria and MitoQ – A Research Update
What is MitoQ? – 30-40 mV PLASMA MEMBRANE Cytoplasm ~ 5x – 140 mV NUCLEUS MITOCHONDRION Matrix ~ 200x Respiratory chain LIPID PEROXIDATION Mitochondria and MitoQ – A Research Update
What is MitoQ? + – 30-40 mV PLASMA MEMBRANE Cytoplasm ~ 5x – 140 mV NUCLEUS MITOCHONDRION Matrix ~ 200x Respiratory chain LIPID PEROXIDATION Mitochondria and MitoQ – A Research Update
Mitochondrial Membrane Mitochondria and MitoQ – A Research Update
What happens in the inner mitochondrial membrane? Electron transport chain Carnitine O-acetyltransferase NADH dehydrogenase (ubiquinone) Carnitine O-octanoyltransferase Electron-transferring-flavoprotein dehydrogenase Cytochrome P450 Electron-transferring flavoprotein Translocase of the inner membrane Succinate dehydrogenase Glutamate aspartate transporter Alternative oxidase Pyrimidine metabolism Cytochrome bc1 complex Dihydroorotate dehydrogenase Cytochrome c Thymidylate synthase (FAD) Cytochrome c oxidase HtrA serine peptidase 2 F-ATPase Adrenodoxin reductase ATP–ADP translocase Heme biosynthesis ATP-binding cassette transporter Protoporphyrinogen oxidase Cholesterol side-chain cleavage enzyme Ferrochelatase Protein tyrosine phosphatase Uncoupling protein Carnitine O-palmitoyltransferase Mitochondria and MitoQ – A Research Update
What makes MitoQ Different? ONE TWO THREE Mitochondria Selective vs Recycling -targeted Broad antioxidant antioxidant Spectrum Mitochondria and MitoQ – A Research Update
Why is this important?
Hepatitis Alzheimer’s CKD Parkinson’s Aging Obesity Mitochondrial dysfunction Blindness Epilepsy & Deafness Rheumatoid CVD Arthritis Multiple Cancer Sclerosis Diabetes Mitochondria and MitoQ – A Research Update
MitoQ Research
Research 50mUSD+ 200+ 70+ published disease papers models NIA funded Interventions Testing Program Clinical Research underway Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondrial Research
Mitochondrial research is only starting Oxphos Calcium ROS homeostatis signalling Mitochondria do ??? Cell death Cell survival Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mouse Strain Mouse at Birth Aged Mouse The new engl and jour nal of medicine Oxidative phosphorylation: Oxidative phosphorylation: Decreased rate of respiration Higher rate of respiration Decreased rate of ATP synthesis Higher rate of ATP synthesis Cl inic a l Impl ic at ions of B a sic R e se a rch Reactive oxygen species: Reactive oxygen species: Increased production Lower production C57BL/6 C57BL/6 Weight gain from high-fat diet nuclear DNA Elizabeth G. Phimister, Ph.D., Editor Shorter median life span (741 days) Mitochondrial Matchmaking Oxidative phosphorylation: Oxidative phosphorylation: Lower rate of respiration Maintained rate of respiration Patrick F. Chinnery, M.B., B.S., Ph.D., and Massimo Zeviani, M.D., Ph.D. Lower rate of ATP synthesis Maintained rate of ATP synthesis Reactive oxygen species: Reactive oxygen species: oxygen species. 2 These observations provided a Although conveniently described as the “batter- Higher production No increased production Conplastic BL/6 NZB ies of the cell” (and, consistent with this analogy, partial explanation for earlier studies in conplas- Less weight gain from high-fat diet amenable to exchange), mitochondria are com- tic mice (i.e., mice in which the nuclear genome plex cellular organelles assembled from proteins from one inbred strain is backcrossed into the Higher median life span (887 days) encoded by two distinct genomes: nuclear chro- cytoplasm of another inbred strain, with the NZB/OlaHsd mosomal DNA and the mitochondrial genome cytoplasmic source always being the female par- mitochondrial (mitochondrial DNA [mtDNA]). Despite its small ent), in which changes were found in learning, DNA NZB/OlaHsd Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Mitochondria and MitoQ – A Research Update
Human Research
Mendus Trial Fibromyalgia and Chronic Fatigue Syndrome • 12 week 3 arm blinded crossover trial • Key results: FM Arm; 24-33% reduction in pain, 10-13% improvement in cognitive function • CFS Blinded Arm; no significant benefit • CFS Open Arm; including increases in energy (26% and 32%), sleep quality (17% and 35%), • mental clarity (18% and 51%), activity (54% and 86%) and verbal reasoning (19% and 30%); as well as a modest reduction in pain at 6-weeks (13%) Mitochondria and MitoQ – A Research Update
Spanish trial The mitochondria-targeted antioxidant MitoQ modulates oxidative stress, inflammation and leukocyte-endothelium interactions in leukocytes isolated from type 2 diabetic patients – Escribano-Lopez et al 2016 169 subjects; 98 with type-2 diabetes (T2D) and 71 control subjects • Study aim was to examine whether MitoQ could reduce oxidative stress and affect metabolic parameters and • leukocyte-endothelium interactions Leukocytes from T2D patients showed increased ROS (free radical) production but MitoQ treatment brought • these values down to those of controls. MitoQ also increased levels of glutathione peroxidase (an ROS- neutralizing enzyme) in both patients and controls. MitoQ treatment significantly reduced the adhesion of leukocytes to endothelial cells in the T2D group • MitoQ treatment also significantly reduced levels of NF κ B-p65 and TNF α in the T2D group but did not change • these levels in the control group. “Overall, our findings provide a better understanding of the pathophysiological mechanisms occurring in • leukocytes/endothelium of T2D patients. They suggest that increased inflammation and oxidative stress, together with NF κ B activation and increased proinflammatory cytokine TNF α , contribute to the enhanced interaction between these cells, which augments the risk of CVD. Importantly, treatment with MitoQ modulates these actions, thus preventing oxidative stress and chronic inflammation, which suggests that this compound has potential beneficial effects for preventing cardiovascular diseases in T2D” Mitochondria and MitoQ – A Research Update
Colorado U trial Mitochondria and MitoQ – A Research Update
Delaware U trial Mitochondria and MitoQ – A Research Update
Planned Human Research Diabetes Multiple Sclerosis Asthma Mitochondria and MitoQ – A Research Update
Mouse Model Research
Recommend
More recommend
